TriLink’s CleanCap® AG (3′ OMe) CleanScript™ IVT Kit provides essential components for mRNA synthesis using co-transcriptional capping by in vitro transcription (IVT). The kit components are sufficient to run 25 x 100 µL or 125 x 20 µL reactions reactions following our recommended IVT protocol with co-transcriptional capping. It includes a cap analog, modified and unmodified nucleotides, IVT enzymes, a reaction buffer, and a control DNA template. Each kit is expected to yield 20-25 mg of capped mRNA.
The kit is designed for:
TriLink mRNA workflow solutions TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organisation (CDMO) for the synthesis of nucleic acids, NTPs and mRNA capping analogs. TriLink has scale-up expertise and unique mRNA, oligonucleotide & plasmid production capabilities for companies focused on therapeutic, vaccine, diagnostic and biopharmaceutical breakthroughs.
- Time and cost savings — Co-transcriptional capping protocol with all necessary reagents for a single-tube reaction providing high yield, fewer steps, and less handling
- High capping efficiency —Protocol with CleanCap AG (3′ OMe) cap analog to produce an optimal cap 1 with over 95% capping efficiency
- Increased mRNA yield — Buffer and kit components formulated using TriLink’s proprietary CleanScript IVT method for up to 10 mg/mL yield (or up to 1 mg mRNA from 5 µg linear plasmid) per 100 µL reaction
- Ultra-low double-stranded RNA (dsRNA) levels — up to 85% dsRNA reduction using CleanScribe RNA Polymerase (in place of wild-type T7 RNA polymerase) in combination with the CleanScript method (instead of standard IVT)
- Enhanced mRNA performance — Robust protein expression and low inflammatory responses from mRNA synthesized with CleanCap AG (3′ OMe), CleanScript method, CleanScribe RNA polymerase, and optional N1-methylpseudouridine
- CleanCap® Reagent AG (3′ OMe), 10 µmol
- Adenosine-5′-Triphosphate, 100 µmol
- Cytidine-5′-Triphosphate, 100 µmol
- Guanosine-5′-Triphosphate, 100 µmol
- Uridine-5′-Triphosphate, 100 µmol
- N1-Methyl-Pseudouridine-5′-Triphosphate, 100 µmol
- AG CleanScribe™ RNA Polymerase Mix, 250 µL
- 10X AG CleanScriptâ„¢ IVT Buffer, 1 mL
- FLuc Control Plasmid, 25 µg
| Product Details | |
| Catalogue No | K-7413 |
| Reaction Sizes | 25 rxns (100 µL scale), 125 rxns (20 µL scale) |
| Recommended Storage | -15 to -25°C |
| Application | In vitro Transcription, co-transcriptional capping, mRNA synthesis |
| Cap | AG Start, Cap 1, CleanCap AG (3′ OMe) |
| Cap Analogs | CleanCap Cap Analogs |
Discover TriLink’s CleanScript IVT Kits
Download the flyer >
TriLink mRNA workflow solutions TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organisation (CDMO) for the synthesis of nucleic acids, NTPs and mRNA capping analogs. TriLink has scale-up expertise and unique mRNA, oligonucleotide & plasmid production capabilities for companies focused on therapeutic, vaccine, diagnostic and biopharmaceutical breakthroughs.
| Cap Analogs | Nucleotides | ||||||
|
CleanCap® cap analogs
|
Modified and unmodified
| ||||||
| trilinkbiotech.com/ cleancap | trilinkbiotech.com/ nucleotides |
| Enzymes | Premade mRNAs |
IVT enzymes
|
10 genes, 3 designs
|
trilinkbiotech.com/ ivtenzymes | trilinkbiotech.com/ premade-mrnas |
Learn more about TriLink CleanCap mRNAs
Download the flyer >
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
Request a Quote
Request Quote
Recent Posts
Email Outage
Due to the ongoing Microsoft outage. We are experiencing issues sending and receiving emails. For all urgent orders or enquiries please contact (AU) 1800 222 287 or (NZ) 0800 222 170.